Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 73
Selected: 0
NCT IDTitle
NCT05368285A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT06455202A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT01460134A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
NCT03358719DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT03068650Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
NCT01156753A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
NCT06727552A Study of Barzolvolimab in Patients With Atopic Dermatitis
NCT02642016A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
NCT01498328A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
NCT07256392Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06650761A Phase I Study of CDX-622
NCT02270372Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
NCT03254927A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
NCT02200380A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
NCT03804944Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT04944862A Study of CDX-0159 in Patients With Prurigo Nodularis
NCT02284971Pilot Study of SBRT and CDX-1127 in Prostate Cancer
NCT05788484A Study of CDX-585 in Patients With Advanced Malignancies
NCT04491084FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
NCT04548869A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
NCT02302339A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
NCT00648102Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
NCT03307746A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma
NCT03688178DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
NCT00709462A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
NCT03580382Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
NCT00323518A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis
NCT03473691Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer
NCT02456701Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
NCT00948961A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
NCT04364230Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
NCT01997333Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
NCT03067935Individual Patient Expanded Access-Glembatumumab Vedotin
NCT00704158Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer
NCT07266402A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT02713828Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
NCT05231122Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT02014909A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
NCT02543645A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
NCT05405660A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
NCT03329950A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
NCT02924038A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
NCT05029999CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
NCT03835533Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
NCT02413827A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
NCT06366750A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT00412828A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
NCT04930783NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
NCT01791686Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease